Project Grant R21EY035454
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$228K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55414, USA
Similar Awards
This $220,463 Project Grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) aims to investigate atypical pathological signaling as a target to regulate retinal vasculopathies over a two-year period from June 2024 to May 2026. The grant will fund research using mouse models and human retinal cell cultures to define the role of the atypical p38 signaling pathway in propagating vascular inflammation and abnormal blood vessel growth in retinal diseases....
The National Eye Institute (NEI) awarded a $184,117 Project Grant (CFDA 93.867 - Vision Research) to Oakland University to investigate the role of G-protein coupled receptors GPR31 and GPR39 in the pathogenesis of diabetic retinopathy. The research aims to determine the affinities and substrate specificities of these receptors for the 12/15-lipoxygenase metabolites 12-HETE and 15-HETE, and to examine the effects of GPR31 and GPR39 gain-or-loss-of-function on retinal endothelial cells and...
The National Eye Institute (NEI) awarded The Ohio State University a 5-year, $513,371 Project Grant under the Vision Research program (CFDA 93.867) to conduct a comprehensive investigation of the role of the cGAS-STING pathway in oxidative retinal damage. The research aims to 1) elucidate the molecular mechanisms governing the escape of self-DNA into the cytosol during oxidative stress, 2) define the activation of cGAS-driven effector pathways in mouse retinal and RPE tissue under acute and...
The National Eye Institute (NEI) has awarded a $2,305,702 Project Grant (CFDA 93.867 - Vision Research) to Vanderbilt University Medical Center to conduct integrative multi-omics research to discover molecular pathways associated with diabetic retinopathy (DR). The project aims to quantify differential transcript and metabolite abundance between participants with type 2 diabetes with and without clinical diagnosis of DR in the Cameron County Hispanic Cohort, and replicate findings in the...
This federal Project Grant award from the National Eye Institute (NEI), under CFDA Program 93.867 (Vision Research), provides $107,727 to support research on the molecular mechanisms underlying the role of the protein REDD1 in the development of diabetic retinopathy. The primary objective is to characterize how diabetes causes allosteric regulation of REDD1, leading to increased protein abundance and retinal pathology. The research will employ genetic mouse models and advanced techniques like AI...
The National Eye Institute (NEI) awarded a $634,731 Project Grant (CFDA 93.867 Vision Research) to the University of Alabama at Birmingham (UAB) to develop an RXR-based therapy for treating diabetic retinopathy. The funding will support research to evaluate the therapeutic impact of intravitreal delivery of RXR agonist microparticles (UAB126-MP and UAB30-MP) to prevent and reverse diabetic retinopathy in mouse models and human retinal cell cultures. The goal is to determine if this targeted...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to investigate the role of myeloid cell transmigration in the progression of non-proliferative diabetic retinopathy. The project aims to determine whether blocking myeloid cell infiltration can halt inflammation and disease progression in the retina, as well as evaluate the impact of disrupting leukocyte-endothelial interactions on diabetic...
The National Eye Institute (NEI) has awarded a Project Grant (CFDA 93.867 Vision Research) totaling $421,600.00 to Tufts Medical Center in Boston, MA. The 5-year grant, awarded on August 1, 2024, aims to delineate the regulatory mechanisms that facilitate neovascular growth and regression in proliferative retinopathies, which are leading causes of blindness. The key research objectives are to: 1) Determine the role of chemokine signaling in facilitating non-resident immune cell recruitment and...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $1,155,000 in funding to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to conduct research on targeting the interleukin-6 (IL-6) cis-trans balance in Müller cell dysfunction associated with diabetic retinopathy (DR). The key objectives are to: 1) identify the intracellular signaling mechanisms that lead to differential effects of IL-6 cis- and...
This federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $440,806 to The Research Foundation For The State University Of New York (RF SUNY) to conduct research on the role of the molecular chaperone p58IPK in protecting retinal neurons from damage due to diabetic retinopathy. The 5-year project aims to define the in vivo function of p58IPK in regulating protein and lipid homeostasis in the diabetic retina through the...